Combination immunotherapy benefits subset of patients with advanced prostate cancer

Combination immunotherapy benefits subset of patients with advanced prostate cancer

Padmanee Sharma, M.D., Ph. D

Phase II trial provides rationale for pursuing further study of dual checkpoint blockade HOUSTON — Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab […]